Purpose The XELAVIRI trial investigated the optimal treatment strategy for patients with
untreated metastatic colorectal cancer. We tested the noninferiority of initial treatment with a …

Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer
of the colon-rectum, that by orphan disease, it is now becoming an important paradigm of …

Objective To assess the real-world patterns of systemic treatment attrition rates among
patients with metastatic colorectal cancer. Methods Databases based from the provincial …

Colorectal cancer (CRC) is the third most common type of cancer and the second leading
cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or …

Background The optimal therapeutic strategy for metastatic colorectal cancer patients is still
a matter of debate. There are no prognostic variables indicating how many lines individual …

Metastatic colorectal cancer (mCRC) is still one of the tumor types with the highest incidence
and mortality. In 2012, colorectal cancer was the second most prevalence cancer among …

Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies
are well-documented treatment options for first-and second-line treatments of metastatic …

Metastatic colorectal cancer (CRC) represents an important health problem in which several
biological predictive and prognostic factors have been identified, including clinical features …

Over the past couple of decades considerable progress has been made in the management
of metastatic colorectal cancers (mCRC) leading to a significant improvement in five-year …

Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve
response rate and prolong median survival over fluorouracil with leucovorin (FU/LV), and …